drugset

drugset / Trial / NCT02875626

Role of Indocyanine Green (ICG) for Detection of Sentinel Nodes in Breast Cancer

NCT02875626 ↗

Completed 80 enrolled Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie

NaSingle-groupOpen-labelDiagnostic

Summary

This is a single-center prospective study evaluating the diagnostic performance and safety of Infracyanine in women with early breast cancer whose the research of sentinel node(s) combines isotopes and Infracyanine.

Timeline

Start: 2016-09
Primary completion: 2019-02
Completion: 2019-03

Publications

Ngo C, Sharifzadehgan S, Lecurieux-Lafayette C, Belhouari H, Rousseau D, Bonsang-Kitzis H, Crouillebois L, Balaya V, Oudard S, Lecuru F, Elaidi RT. Indocyanine green for sentinel lymph node detection in early breast cancer: Prospective evaluation of detection rate and toxicity-The FLUOBREAST trial. Breast J. 2020 Dec;26(12):2357-2363. doi: 10.1111/tbj.14100. Epub 2020 Oct 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Indocyanine Green	Diagnostic / imaging agent	2 ml	Other
Subject	Indocyanine Green	Diagnostic / imaging agent	2.5 mg/ml	Other
Subject	Indocyanine Green	Diagnostic / imaging agent	3.2 unknown	Other

Indications